Search

everythinglearnresearchcommunity

for

Search:↓

Enhancing CD8+ T cell function to induce ferroptosis in tumor cells may help treat skin melanoma.

RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

NXC736 significantly reduced hair loss in mice with alopecia areata.

Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.

Reducing CD8+ T cell growth can stabilize alopecia areata.

Modulating the BTNL2 pathway can prevent hair loss in mice.

Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

A teenager had both alopecia areata and vitiligo, which are rare to occur together.

Skin bacteria can help wound healing by activating certain immune cells.

Immune changes and specific genes contribute to male hair loss.

The gut microbiome affects the development of alopecia areata.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.

Blocking CCR5 can prevent and improve hair loss in alopecia areata.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

Enhancing Tregs can protect against alopecia areata.

Overexpression of IKZF1 and Ikaros causes hair loss in mice similar to alopecia areata.

Too much IKZF1 and Ikaros protein may cause alopecia areata.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Targeting CXCL10 may help treat alopecia areata.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

Exosomes from certain cells can improve hair regrowth by changing the immune response.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss in Discoid Lupus.

Being allergic to linalool, a common fragrance ingredient, might contribute to developing frontal fibrosing alopecia.

The humanized AA mouse model is better for testing new alopecia areata treatments.